arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AtriCure, Inc.

ATRC
$41.41 ▲ +1.91 (+4.82%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Neutral
auto_awesome

Analytical Summary

AtriCure, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.0B
Dividend Yield
Revenue Growth 12.8%
Op. Margin 6.3%
ROIC 1.6%
FCF / Share $0.38
Trailing P/E 230.1x
Price / Book 4.1x
FCF Yield 0.9%
Debt / Equity 0.12
info Valuation on last close. End-of-day price, Aug 7, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$153.60M
↑ +12.8%
Net Income Profit after all expenses
$8.96M
↑ +8191.7%
Operating Margin Operating profit as % of sales
6.3%
↑ +1589.7% 25th
FCF / Share Free cash flow per share
$0.38
↑ +333.2%
Long-Term Debt Long-term obligations
$61.00M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
37
Returns
41
Financial Health
61
Cash Quality
4

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters